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Abstract
We propose a dual-hormone delivery strategy by exploiting deep reinforcement
learning (RL) for people with Type 1 Diabetes (T1D). Specifically, double dilated
recurrent neural networks (RNN) are used to learn the hormone delivery strategy,
trained by a variant of Q-learning, whose inputs are raw data of glucose & meal
carbohydrate and outputs are dual-hormone (insulin and glucagon) delivery. With-
out prior knowledge of the glucose-insulin metabolism, we run the method on
the UVA/Padova simulator. Hundreds days of self-play are performed to obtain a
generalized model, then importance sampling is adopted to customize the model for
personal use. In-silico the proposed strategy achieves glucose time in target range
(TIR) 93% for adults and 83% for adolescents given standard bolus, outperforming
previous approaches significantly. The results indicate that deep RL is effective in
building personalized hormone delivery strategy for people with T1D.
1 Introduction
Diabetes is a lifelong condition that affects an estimated 425 million people worldwide [1]. Delivering
an optimal insulin dose to T1D subjects is one of the long-standing challenges since 1970s [2, 3].
Previously the quality of life of T1D subjects heavily relies on the accuracy of human-defined models
& features of the delivery strategy. In recent years, deep learning (DL) has provided new ideas and
solutions to many healthcare problems [4], empowered by increasing availability of medical data
and rapid progress of analytic tools, e.g. RL. However, several reasons hinder us from building an
efficient RL model to solve problems in chronic diseases. Firstly, collected from a dynamic interaction
between human and environment, RL medical data are limited and expensive [5]. In addition, different
from playing Atari in virtual environment [6], RL costs heavily to ’explore’ possibilities on human
beings in terms of prices and safeness. Finally, the variability of physiological responses to the same
treatment can be very large for different people with T1D [7]. It is difficult to build a versatile model
suitable for wide subjects. These reasons lead to little progress of using RL in chronic illnesses.
To overcome the obstacles, we propose a two-step framework to apply deep RL in chronic illnesses,
and use T1D as a study case. T1D is chosen because it is a typical disease that requires dynamic
treatment consistently. A generalized DNN for hormone delivery strategy is pre-trained using a
variant of Q-learning as the first step. We use double dilated recurrent neural network (DRNN) to
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build a model for multi-dimensional medical time series, in which each basal hormone delivery (at
five minutes intervals) are considered as an action determined by a stochastic policy, and glucose
levels and TIR are considered as the reward. Secondly, by adopting weights & features from the last
step, important sampling are implemented to customize the model personalized using individual data.
We use the UVA/Padova T1D Simulator, a popular glucose-insulin dynamics simulator which has
been accepted by the Food and Drug Administration (FDA) [8], as the environment. It can generate
T1D subjects data with high variability in meals, body conditions and other factors. During the
training, hundreds days of ’self-play’ trials are performed to obtain a generalized model for the
dual-hormone closed-loop basal delivery with standard bolus. In the test, 10 adults and 10 adolescents
are tested within 6 months period of time. The results show that TIRs achieve 93% for adults and
84% for adolescents in-silico, which significantly improve the state-of-the-art performances.
2 Related Work and Preliminaries
The rapid growth of continuous glucose monitoring (CGM) and insulin pump therapy have motivated
use of a closed-loop system, known as the artificial pancreas (AP) [9, 10, 11, 12]. Many algorithms
are developed and verified as closed-loop single/dual hormone delivery strategies [13] that are mostly
based on control algorithms [14, 15]. Machine learning (ML) is leveraged in glucose management in
[16, 17]. DNN is a new method in glucose management with fully connected [18], CNN-based [19],
RNN-based [20], physiological-based [21] networks. It has been shown that dilated RNN performs
well in processing long-term dependencies [22]. By updating control parameters in gradient, RL
is adopted recently [23, 12, 24]. To accelerate the learning process, prioritized experience replay
samples important transitions more frequently [25]. Before submission we find an RL environment
was built in simulator of 2008 version [26], while we use a simulator of 2012 version.
We see the problem an infinite-state Markov decision process (MDP) with noises. An MDP can
be defined by a tuple 〈S,A,R, T , γ〉 with state S, action A, reward function R : S × A 7→
[Rmin, Rmax], transition function T , and discount factor γ 7→ [0, 1]. At each time period, the
agent takes an action a ∈ A, causes the environment from some state s ∈ S to transit to
state s′ with probability T (s′, s, a) = P (s′|s, a). A policy pi specifies the strategy of select-
ing an action. RL’s goal is to find the policy pi mapping states to actions that maximizes the
expected long-term reward. A Q-function Qpi(s, a) can be defined to computed this reward
Qpi(s, a) = R(s, a) + γ
∑
s′ P (s
′|s, a)∑a′ pi(s′, a′)Qpi(s′, a′). The optimal action-value func-
tion Q∗(s, a) = maxpi Qpi(s, a) offers the maximal values that can be determined by solving the
Bellman equation Q∗(s, a) = E [R(s, a) + γ
∑
s′ P (s
′|s, a)maxa′ Q∗(s′, a′)].
3 Methods
In the hormone delivery problem, we use a multi-dimensional data as the input D. The data includes
blood glucose G (mg/dL), meal data M (g) manually record by individuals, corresponding meal
bolus B (U). Dual-hormone (basal and glucagon) delivery is considered as actions A. In this case
D can be denoted as D = {G,M, I, C} = [d1, · · · , dL]T ∈ RL×4 where L is the data length, I is
the total insulin including bolus B and basal plus the glucagon C. We use the latest 1 hour data (12
samples) as current state st = [dt−11 · · · , dt−1, dt]T. Here B is computed from M with a standard
bolus calculator B ∝ M divided by the body weight. Then the problem can be seen as an agent
interacting with an environment over time steps sequentially. Every five minutes, an observation
ot = st + et can be obtained, and an action at is taken. The action can be chosen from three options:
do nothing, deliver basal insulin, or deliver glucagon. The amount of basal insulin and glucagon is
a small constant that determined by the subject profile in advance. To maintain the BG in a target
range, we define a reward carefully that the agent receives in each time step
rt =

1 90 ≤ Gt ≤ 140
0 70 ≤ Gt < 90 & 140 < Gt ≤ 180
−0.4− (Gt − 180)/200 180 < Gt ≤ 300
−0.6 + (Gt − 70)/100 30 ≤ Gt < 70
−1 else
(1)
The goal of the agent is to learn a personalized basal insulin and glucagon delivery strategy in a short
period of time (using limited data) for each individual. Here we propose a two-step learning approach
to build the dual-hormone delivery model.
2
3.1 Generalized DQN training
We build an interactive environment in simulator, and dilated RNN is employed as the DNN.
Dilated RNN is used because it has larger receptive field that is crucial for glucose time series
processing [20]. Double DQN weights θ1, θ2 in the simulator are trained because it has been
proved as a robust approach to solve overestimations. Action network and value network are
trained JDQ(Q) = (R(o, a) + γQ(o′, arg maxaQ(o
′, a; θ1); θ2)−Qi(o, a; θ1))2. The pseudo-code
is sketched in Algorithm 1.
Algorithm 1 Generalized model training
1: Inputs: Initializing environment E , historical data H , update frequency T, two dilated RNN of
random weights θ1, θ2, respectively.
2: repeat
3: sample action from a ∼ pi(Qθ1 , ε), observe (o′, r) in E(Is)
4: store (o, a, r, o′) into replay buffer B
5: sample a mini-bath uniformly from B and calculate loss JDQ(Q)
6: perform a gradient descent to update θ1, θ2
7: if t mod T = 0 then θ2 ← θ1 end if
8: until converge or reach the number of iterations
The agent explores random hormone delivery actions under policy pi that is ε-greedy with respect to
Qθ1 in simulator. It is similar to playing Atari games, so the agent can ’self-play’ in simulator for
long time. Some human intervention/demonstration at the beginning of the RL process can reduce
the training time slightly, but in our case it is not necessary. At the end of this step, a DRNN with
weights θ is obtained as the generalized model.
3.2 Personalized DQN training
In this step we refine the model and customize it for the personal use. Weights and features obtained
from the last step are updated using limited data with an importance sampling [25] and safety
constraints. It gives better actions (leading to no hyperglycemia or hypoglycemia) higher probability
and worse demonstrations lower probability. Details are shown in Algorithm 2.
Algorithm 2 Personalized DQN training using imprtance sampling
1: Inputs: Initialized with environment E, historical data H , generalized Q-function Q with weights
θ1, replay buffer B, target weights θ2, update frequency T
2: generate D as a merge of B and experience collected from H
3: calculate importance probability Pr from H
4: repeat
5: sample action from policy a ∼ pi(Qθ, ε), observe (o′, r)
6: store (o, a, r, o′) in D, overwriting the oldest samples previously merged from B
7: sample a mini-batch from D with modified importance sampling Pr
8: calculate loss J(Q) = JDQ(Q)
9: perform a gradient descent update θ and the importance
10: if t mod T = 0 then θ2 ← θ1 end if
11: until converge or reach the number of iterations
4 Experiment Results
We compare the results with the following experiment setup (details in supplementary materials): 1.
bolus calculator + constant basal insulin (BC); 2. bolus calculator + insulin suspension + carbohydrate
recommendation (BC+IS+CR) [27]; 3. ours: bolus calculator + generalized RL model (BC+RL)
(Algorithm 1); 4. ours: bolus calculator + RL intelligent basal (BC+IB) (Algorithm 1, 2)
In experiments we used the TIR ([70, 180] mg/dL), the percentage of hypoglycemia (< 70 mg/dL)
and hyperglycemia (> 180 mg/dL) as the metrics to measure the performance. In general, either
3
Table 1: Results of different experiment setup
(%) Method TIR Hypo Hyper
Adult
BC 81.91±8.66‡ 5.29±3.93‡ 12.80±8.67‡
BC+IS+CR 87.62±7.57‡ 2.36±1.44‡ 10.01±7.35‡
BC+RL 89.16±5.04 1.92±1.36 8.92±5.38
BC+IB 93.12±4.48 1.25±1.32 5.63±3.29
Adolescent
BC 61.68±10.95‡ 9.04±7.22‡ 29.28±11.16‡
BC+IS+CR 74.55±9.61† 2.38±1.82† 23.07±7.26‡
BC+RL 74.89±8.58 2.36±2.19 22.75±8.63
BC+IB 83.39±8.03 2.10±1.56 14.51±9.98
∗p ≤ 0.05 †p ≤ 0.01 ‡p ≤ 0.005
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(a) An adult simulation
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(b) An adolescent simulation
Figure 1: Performance of the four experiment setup on an adult subject and an adolescent subject
in a 6-month period: (Top-to-bottom) BC, BC+IS+CR, BC+RL (ours), BC+IB (ours), distribution
of carbohydrate intake. The average BG levels for 180 days are shown in solid blue lines, and the
hypo/hyperglycemia regions are shown in dotted green/red lines. The gray lines correspond to glucose
levels in every day of the trial, and the blue shaded regions indicate the standard deviation.
higher TIR or lower Hypo/Hyper indicates better glycemia control. These evaluation metrics are
preferred in diabetes clinic [28]. Table 1 presents the overall performance of the experiment setup on
the adult and adolescent subjects. For adult subjects, the IB model achieves the best performance, and
increases the mean TIR by 11.21% (p ≤ 0.005) compared with the BC setup. In the adolescent case,
the IB model obtains the best TIR of 83.39%. In both cases, the IB model outperforms the controller
with IS and CR on both TIR and Hypo/Hyper results with considerable improvements.
To observe the model performance on the specific BG levels, we visualize the BG curves of two
subjects over 6-month testing period in Figure 2. For the adult curves at the left column, the
performance is basically in accordance with statistical results in Table 1, and the IB model avoids many
hypoglycemia events during the night. At the right column, it can be observed that implementation
of the IB model significantly helps to reduce the overall BG levels and increase TIR by making the
mean curve flat and stable. Surprisingly, standard CNN or LSTM cannot achieve such good (or close)
performances as dilated RNN has achieved.
4
5 Conclusion
We propose an intelligent basal hormone delivery algorithm and employ deep RL in glucose manage-
ment. A dilated RNN is used in double DQN, and a personalized model is obtained from generalized
pre-trained model. The results outperform many existing work significantly.
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